Sentinel Oncology Pipeline
P70S6 Kinase (P70S6K) PARTNERED
The enzyme, p70S6 kinase (p70S6K) is a serine-threonine kinase and is a key component of the phosphoinositide 3 kinase (PI3K) pathway. The pathway is vital for the growth and survival of cancer cells. Sentinel is developing selective inhibitors as a first in class approach under exclusivity with a pharmaceutical partner.
Checkpoint Kinase 1 (Chk1)
Chk1 belongs to a family of proteins known as kinases and fulfils a crucial role in sensing and responding to DNA damage. Sentinel Oncology is developing a new class of small molecule, selective CHK1 inhibitors designed for use as chemosensitizers and radiosensitizers.
FMS-like tyrosine kinase 3 (FLT3)
Mutations in the FLT3 gene are amongst the most frequent genetic defects found in acute myeloid leukemia (AML). Sentinel Oncology has developed a novel lead series of small molecule drugs which act as potent inhibitors of FLT3 and represent an excellent opportunity to develop pre-clinical candidate drugs... read more
Poly(ADP-ribose) polymerase 1 (PARP1)
The DNA repair enzyme, PARP1, is a well-validated target for anti-cancer therapy and inhibitors are now being evaluated in clinical trials. The finding that PARP1 inhibitors alone have cytotoxic effects in BRCA1- and BRCA2- as well as for PTEN deficient cells has led to great interest in this class of inhibitors. Sentinel Oncology PARP1 inhibitors show promise in cellular models of cancer and we are seeking partners to license the programme and develop best in class PARP1 drugs... read more
Targeted Synergy (TS)
Lack of therapeutic index is a common problem with many oncology drugs and can be driven by poor tolerability and/or lack of efficacy. To address this issue, Sentinel Oncology is developing an innovative new strategy for cancer treatment called Targeted Synergy that has the potential to deliver improved safety and efficacy by exploiting the tumour microenvironment. Our approach is differentiated over other approaches by delivering two distinct activities through the action of one drug molecule. To find out more please contact busdev@sentineloncology.com...